Delayed
Nasdaq
20:38:17 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
10.94
USD
|
+2.05%
|
|
+5.19%
|
+43.57%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,206
|
81.76
|
49.56
|
69.72
|
-
|
-
|
Enterprise Value (EV)
1 |
1,752
|
81.76
|
49.56
|
69.72
|
69.72
|
69.72
|
P/E ratio
|
-11.6
x
|
-0.37
x
|
-0.32
x
|
-1.69
x
|
-1.18
x
|
-19.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-17,422,944
x
|
-430,239
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-18,070,929
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.98
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,446
|
6,489
|
6,504
|
6,504
|
-
|
-
|
Reference price
2 |
342.2
|
12.60
|
7.620
|
10.72
|
10.72
|
10.72
|
Announcement Date
|
07/03/22
|
31/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.138
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-126.6
|
-190
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-155.6
|
-226.5
|
-159.2
|
-43.72
|
-69.57
|
-11.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-156.8
|
-225.2
|
-156.1
|
-42.33
|
-68.73
|
-11.7
|
Net income
1 |
-37.74
|
-156.8
|
-223.2
|
-156.1
|
-42.33
|
-68.73
|
-11.7
|
Net margin
|
-27,346.38%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-56.60
|
-29.60
|
-34.40
|
-24.00
|
-6.350
|
-9.047
|
-0.5500
|
Free Cash Flow
|
-
|
-122.1
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/02/21
|
07/03/22
|
31/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-43.02
|
-53.75
|
-54.29
|
-58.72
|
-56.65
|
-56.8
|
-33.89
|
-16.57
|
-20.43
|
-13.02
|
-14.53
|
-15.05
|
-15.35
|
-15.65
|
-17.76
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-43.66
|
-54.29
|
-54.6
|
-59.6
|
-56.6
|
-54.45
|
-57.07
|
-18.66
|
-67.43
|
-12.92
|
-14.53
|
-15.07
|
-15.4
|
-15.75
|
-17.66
|
Net income
1 |
-43
|
-55.35
|
-54.6
|
-58.99
|
-56.22
|
-53.84
|
-57.07
|
-18.66
|
-67.43
|
-12.92
|
-14.53
|
-15.07
|
-15.4
|
-15.75
|
-17.66
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-6.600
|
-9.000
|
-8.400
|
-9.200
|
-8.600
|
-8.200
|
-8.800
|
-2.800
|
-10.40
|
-1.990
|
-2.230
|
-2.300
|
-2.335
|
-2.310
|
-2.350
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
07/03/22
|
16/05/22
|
12/08/22
|
14/11/22
|
31/03/23
|
11/05/23
|
14/08/23
|
13/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
454
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-122
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-60.8%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
86.10
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
57.8
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/02/21
|
07/03/22
|
31/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
10.72
USD Average target price
27.67
USD Spread / Average Target +158.08% Consensus |
1st Jan change
|
Capi.
|
---|
| +43.57% | 69.72M | | +26.17% | 42.68B | | -4.11% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.64% | 24.94B | | -21.54% | 18.96B | | +27.59% | 12.3B | | -2.99% | 11.95B | | -1.76% | 11.55B |
Other Biotechnology & Medical Research
|